MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)Business Wire • 05/17/23
MindMed a ‘Speculative Buy' ahead of key trial data readouts, broker saysProactive Investors • 05/09/23
MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing StrategyBusiness Wire • 05/02/23
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business UpdateBusiness Wire • 05/01/23
MindMed stock jumps 4.5% after psychedelics company reports positive findings in trial of LSD as treatment for major depressive disorderMarket Watch • 04/14/23
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)Business Wire • 04/14/23
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate SecretaryBusiness Wire • 04/13/23
MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health ConferencePRNewsWire • 12/01/22
MindMed price target lowered by Canaccord analysts after Phase 2a US clinical trial shelvedProactive Investors • 11/21/22